title: [Coinfection with HIV and HCV--epidemiologic, diagnostic, clinical and therapeutic implications].
abstract: Because of shared transmission pathways, coinfection with HIV and HCV is common. Besides evidence is accumulating that HIV infection may be a cofactor for heterosexual and perinatal transmission of HCV infection. The increasing survival of patients on HAART has emphasized the importance of treating liver disease because co-infected patients are now often dying of their liver disease. There is a common opinion that HIV infection causes rapid and more severe course of HCV-related liver disease. The impact of HCV infection on HIV disease progression is controversial. The treatment of patients co-infected with HIV and HCV is difficult. Therapeutic options depend on immunological status of patients and severity of liver disease. In addition hepatotoxicity and drug interactions should be considered.
authors.affiliation: Katedra i Klinika Chorób Zakaźnych i Hepatologii, Uniwersytet Medyczny w Lodzi.
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Jabłonowska
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000008:administration & dosage*; D018450:Disease Progression; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D019698:Hepatitis C, Chronic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage; D012254:Ribavirin / Q000008:administration & dosage; D012307:Risk Factors
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin